Form 4: Ocular Therapeutix Director Merilee Raines Receives Stock and Options Grant

Director Merilee Raines of Ocular Therapeutix, Inc. was granted 12,000 restricted stock units and options to purchase 36,000 shares of common stock on July 24, 2024.

Summary

• On July 24, 2024, Merilee Raines, a director of Ocular Therapeutix, Inc., received a grant of 12,000 restricted stock units (RSUs) and options to purchase 36,000 shares of the company's common stock.
• The RSUs will vest on the first anniversary of the grant date or immediately prior to the next annual meeting of stockholders, contingent upon continued service on the board.
• The options, with an exercise price of $7.91, also vest on the first anniversary of the grant date or immediately prior to the next annual meeting of stockholders, subject to continued board service.
• Following the reported transaction, Raines directly owns 32,933 shares of Ocular Therapeutix common stock and options to purchase 36,000 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of the shareholders.
• Vesting is tied to continued service, incentivizing long-term commitment to the company.

Future Outlook

The RSUs and options vest based on continued service on the board, suggesting an expectation of ongoing involvement.

Industry Context

Grants of stock options and restricted stock units are common practices to compensate and incentivize board members in publicly traded companies, aligning their interests with shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the pharmaceutical and biotech industries.
• Companies like Regeneron and Amgen also use stock options and RSUs as part of their director compensation packages.
• The vesting schedules are typical, often tied to continued service and annual meetings.

Stakeholder Impact

• Shareholders may view the grants positively as they align director interests with company performance.
• Employees may see this as a sign of confidence in the company's future.

Key Dates